Novo Nordisk is investing in a new production facility in Denmark to manufacture rare disease drugs, with completion expected in 2027. The facility will create 400 permanent jobs and utilize advanced technology to meet global demand for life-changing medicines. The company’s focus on rare diseases includes hemophilia treatments, such as concizumab, which has received regulatory approval in Canada and Europe. Novo Nordisk also continues to expand its manufacturing capacity for metabolic medicines in Europe and the U.S., including recent acquisitions of Catalent sites. The company expects to complete the Catalent transactions and acquisition in the near future.
Source link
Novo Nordisk Adds to Manufacturing Capacity, Pumping Billions Into New Rare Disease Site
